Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EndoTAG-1 plus gemcitabine versus gemcitabine alone for locally advanced and/or metastatic pancreatic cancer
CTR20202537Phase 3Suspended
- Sponsor
- SynCore Biotechnology
- Start
- Aug 2021
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of EndoTAG-1, gemcitabine in pancreatic cancer (PC), sponsored by SynCore Biotechnology. Started Aug 2021; status: suspended.
02
Drugs
EndoTAG-1gemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20202537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202537.